Statin Treatment of COVID-19.
作者信息
Fedson David S
出版信息
Am J Cardiol. 2020 Dec 1;136:171-173. doi: 10.1016/j.amjcard.2020.09.050. Epub 2020 Sep 28.
Abstract
摘要
相似文献
1
Statin Treatment of COVID-19.他汀类药物治疗新型冠状病毒肺炎
Am J Cardiol. 2020 Dec 1;136:171-173. doi: 10.1016/j.amjcard.2020.09.050. Epub 2020 Sep 28.
2
Statin therapy in COVID-19 infection.新冠病毒感染中的他汀类药物治疗。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259. doi: 10.1093/ehjcvp/pvaa042.
3
Statin therapy in COVID-19 infection: much more than a single pathway.新冠病毒感染中的他汀类药物治疗：远不止单一途径。
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):410-411. doi: 10.1093/ehjcvp/pvaa055.
4
Use of statins in patients with COVID-19.他汀类药物在新冠肺炎患者中的应用。
QJM. 2020 Aug 1;113(8):604-605. doi: 10.1093/qjmed/hcaa172.
5
Response to: Use of statins in patients with COVID-19.回应：新冠病毒疾病患者使用他汀类药物的情况
QJM. 2020 Aug 1;113(8):606-607. doi: 10.1093/qjmed/hcaa173.
6
Meta-analysis of Effect of Statins in Patients with COVID-19.他汀类药物对新型冠状病毒肺炎患者影响的荟萃分析
Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.
7
Statins in COVID-19: A new ray of hope.新冠疫情中的他汀类药物：一线新希望。
Heart Lung. 2020 Nov-Dec;49(6):887-889. doi: 10.1016/j.hrtlng.2020.07.012. Epub 2020 Aug 11.
8
Are certain drugs associated with enhanced mortality in COVID-19?某些药物是否与新冠病毒疾病（COVID-19）死亡率升高有关？
QJM. 2020 Jul 1;113(7):509-510. doi: 10.1093/qjmed/hcaa103.
9
Are statins safe in patients with COVID-19?他汀类药物对新冠肺炎患者安全吗？
J Clin Lipidol. 2020 Jul-Aug;14(4):396-397. doi: 10.1016/j.jacl.2020.06.009. Epub 2020 Jun 22.
10
Statins and other drugs: Facing COVID-19 as a vascular disease.他汀类药物及其他药物：将新冠病毒病视为一种血管疾病来应对
Pharmacol Res. 2020 Sep;159:105033. doi: 10.1016/j.phrs.2020.105033. Epub 2020 Jun 17.
引用本文的文献
1
Why antidiabetic drugs are potentially neuroprotective during the Sars-CoV-2 pandemic: The focus on astroglial UPR and calcium-binding proteins.为何抗糖尿病药物在新冠疫情期间可能具有神经保护作用：聚焦于星形胶质细胞未折叠蛋白反应和钙结合蛋白
Front Cell Neurosci. 2022 Jul 29;16:905218. doi: 10.3389/fncel.2022.905218. eCollection 2022.
2
Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.氟伐他汀增强 IL-33 介导的肥大细胞 IL-6 和 TNF 的产生。
Cell Immunol. 2022 Jan;371:104457. doi: 10.1016/j.cellimm.2021.104457. Epub 2021 Nov 24.
3
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.阿托伐他汀治疗新冠病毒疾病成年住院患者：一项双盲随机对照试验。
Int J Cardiol Heart Vasc. 2021 Oct;36:100875. doi: 10.1016/j.ijcha.2021.100875. Epub 2021 Sep 14.
4
The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis.他汀类药物的使用与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Am J Cardiovasc Drugs. 2022 Mar;22(2):167-181. doi: 10.1007/s40256-021-00490-w. Epub 2021 Aug 3.
5
Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.新型冠状病毒肺炎中的脂质稳态和甲羟戊酸途径：基本概念和潜在治疗靶点。
Prog Lipid Res. 2021 Apr;82:101099. doi: 10.1016/j.plipres.2021.101099. Epub 2021 Apr 26.
6
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.他汀类药物与 COVID-19 的临床结局：观察性研究的荟萃分析。
Diabetes Metab. 2021 Nov;47(6):101220. doi: 10.1016/j.diabet.2020.101220. Epub 2020 Dec 23.
本文引用的文献
1
Meta-analysis of Effect of Statins in Patients with COVID-19.他汀类药物对新型冠状病毒肺炎患者影响的荟萃分析
Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.
2
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.高血压合并 COVID-19 患者住院期间持续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与临床结局改善相关。
J Infect Dis. 2020 Sep 14;222(8):1256-1264. doi: 10.1093/infdis/jiaa447.
3
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
4
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.血管紧张素受体阻滞剂（ARBs）、血管紧张素转换酶抑制剂（ACEis）和他汀类药物对养老院居民 COVID-19 感染临床结局的影响。
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2. doi: 10.1016/j.jamda.2020.06.018. Epub 2020 Jun 15.
5
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
6
Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.阿托伐他汀与入住重症监护病房的COVID-19患者死亡风险降低相关：一项回顾性队列研究。
Crit Care. 2020 Jul 14;24(1):429. doi: 10.1186/s13054-020-03154-4.
7
Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework.从损伤反应框架看 COVID-19 的发病机制。
mBio. 2020 Jul 2;11(4):e01175-20. doi: 10.1128/mBio.01175-20.
8
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.住院期间使用他汀类药物与 COVID-19 患者的死亡率降低相关。
Cell Metab. 2020 Aug 4;32(2):176-187.e4. doi: 10.1016/j.cmet.2020.06.015. Epub 2020 Jun 24.
9
Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?
Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1818-1829. doi: 10.1161/ATVBAHA.120.314558. Epub 2020 Jun 8.
10
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
Zotero 插件